Tenderwize
Retour à la recherche

Open-house biologics rebate agreement for Triptorelin embonate

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 29, 2027 · 399 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-22 - Triptorelin embonat

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Participation is limited to pharmaceutical entrepreneurs meeting AMG seat and authorisation requirements for the releva...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Conclusion of pharmaceutical rebate agreements under Section 130a(8) SGB V for the active substance Triptorelin embonate.
  • Open-house model with uniform terms for all suitable pharmaceutical companies; no individual contract negotiations.
Afficher le résumé complet

Open-house pharmaceutical supply arrangement in Germany for Triptorelin embonate (CPV 33600000) led by Techniker Krankenkasse with hkk and HEK as participating buyers. The procedure is non-exclusive, with no individual negotiations and open accession possible throughout the contract period. The contract term runs from 01.10.2025 to 30.09.2027 at the latest, with automatic earlier end if patent/market exclusivity expires. No contract value is stated. Procurement documents are available via the portal, but only the notice/XML text was analyzed, not the full documents.

Risques

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Participation is limited to pharmaceutical entrepreneurs meeting AMG seat and authorisation requirements for the releva...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its registered seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-house biologics rebate agreement for Triptorelin embonate

Open-house agreement for pharmaceutical rebate contracts concerning the active substance Triptorelin embonate. Scope is nationwide in Germany and the arrangement is non-exclusive, with uniform conditions and no individual negotiations. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Sep 2025 - Sep 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 29, 2027

Détails de la procédure

Date de publication
07 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
521224-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3